Drug intelligence / Profile preview

QL-1200186

Development stage: Preclinical
Lead developer: Qilu Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

QL-1200186 is a potent, highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2), specifically targeting the pseudokinase regulatory domain. It is an orally active small molecule that suppresses interferon-γ (IFNγ) production following interleukin-12 (IL-12) stimulation and has demonstrated significant improvement in skin lesions in psoriatic mouse models. QL-1200186 is being investigated as a clinical drug candidate for the treatment of psoriasis and other autoimmune diseases, including systemic lupus erythematosus[1][2][3][4][8].

Targets

TYK2 JH2 (Tyrosine kinase 2 Janus homology 2 pseudokinase domain)JAK1 JH2 (JAK1 pseudokinase domain)

Beyond the preview

Go deeper on QL-1200186.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL-1200186.

Explore the full profile